SCHEMBL3559489

SCHEMBL3559489

NS(=O)(=O)c1cncc(B(O)O)c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
APLNR P35414 1/20 0.58
CA1 P00915 10/20 0.39
CA2 P00918 10/20 0.39
PIK3CD O00329 1/20 0.38
PIK3CG P48736 1/20 0.38
CA9 Q16790 8/20 0.35
CA12 O43570 6/20 0.35
CA4 P22748 3/20 0.35
CA7 P43166 3/20 0.35
CA14 Q9ULX7 2/20 0.35
CA3 P07451 2/20 0.35
CA6 P23280 2/20 0.35
CA13 Q8N1Q1 2/20 0.35
CA5A P35218 1/20 0.35
PLA2G7 Q13093 1/20 0.35
CA5B Q9Y2D0 1/20 0.35
ENPP2 Q13822 1/20 0.34
NAPRT Q6XQN6 1/20 0.33
KDM4E B2RXH2 1/20 0.32
MEN1 O00255 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29956810 1.00 APLNR (0.58) APLNRCA1CA2PIK3CDPIK3CG
SCHEMBL247773 0.81 ENPP2 (0.52) APLNRPIK3CDPIK3CGENPP2NAPRT
SCHEMBL11690551 0.79 APLNR (0.71) APLNRCA1CA2PIK3CDPIK3CG
SCHEMBL2561753 0.77 CDK8 (0.48) CA1CA2PIK3CDPIK3CGCA9
SCHEMBL15870163 0.77 PIK3C3 (0.42) ENPP2MEN1RAB9AKMT2A
SCHEMBL15870055 0.77 ENPP2 (0.35) APLNRENPP2NAPRT
SCHEMBL18247080 0.74 APLNR (1.00) APLNRCA1CA2PIK3CDPIK3CG
SCHEMBL28967087 0.73 ENPP2 (0.36) CA1CA2CA4CA7CA14
SCHEMBL12804923 0.73 ALDH1A1 (0.48) PIK3CDPIK3CGKDM4EMEN1MAPT
SCHEMBL585145 0.72 CA2 (0.64) CA1CA2CA9CA12CA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2014106800-A2 SUBSTITUTED 2-AMINO PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) 2014-07-10 WO disclosed
EP-2468727-A1 Pyridine and pyrimidine derivatives as MGLUR2 antagonists F. Hoffmann-La Roche AG (CH) 2012-06-27 EP disclosed
US-8183262-B2 Central nervous system disorders; metabotropic glutamate receptors (mGluR); 2-(4-Pyridin-3-yl-imidazol-1-yl)-4-trifluoromethyl-6-(4-trifluoromethyl-phenyl)-pyrimidine HOFFMANN-LA ROCHE INC. (US) 2012-05-22 US disclosed
US-7642264-B2 Phenyl-substituted pyrimidine derivatives as mGluR antagonists HOFFMAN-LA ROCHE INC. (US) 2010-01-05 US disclosed
US-20090318474-A1 PYRIDINE AND PYRIMIDINE DERIVATIVES AS MGLUR 2 ANTAGONISTS GATTI MCARTHUR SILVIA 2009-12-24 US disclosed
EP-2001849-A1 PYRIDINE AND PYRIMIDINE DERIVATIVES AS MGLUR2 ANTAGONISTS F. Hoffmann-Roche AG (CH) 2008-12-17 EP disclosed
US-20070232583-A1 Pyridine and pyrimidine derivatives as mGIuR2 antagonists HOFFMANN-LA ROCHE INC. 2007-10-04 US disclosed
WO-2007110337-A1 PYRIDINE AND PYRIMIDINE DERIVATIVES AS MGLUR2 ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2007-10-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070232583-A1 Pyridine and pyrimidine derivatives as mGIuR2 antagonists P2RX2, P2RY2, P2RX1 APLNR 2864/4885CA1 4351/4885CA2 2101/4885
US-20090318474-A1 PYRIDINE AND PYRIMIDINE DERIVATIVES AS MGLUR 2 ANTAGONISTS GRM2, GRM1, GRM3 APLNR 1015/4885CA1 3811/4885CA2 1337/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.